2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1

BACKGROUND: In the pivotal clinical trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229), the adjuvanted recombinant zoster vaccine (RZV) showed high efficacy against herpes zoster and postherpetic neuralgia. The incidence of reported solicited events was higher in RZV compared with placebo recipie...

Descripción completa

Detalles Bibliográficos
Autores principales: Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Hyung Kim, Joon, Levin, Myron J, Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810576/
http://dx.doi.org/10.1093/ofid/ofz360.2457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810576/
http://dx.doi.org/10.1093/ofid/ofz360.2457

Ejemplares similares